Format

Send to

Choose Destination
Cancers (Basel). 2019 Jul 26;11(8). pii: E1055. doi: 10.3390/cancers11081055.

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

Author information

1
Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, 00168 Rome, Italy. ernesto.rossi@policlinicogemelli.it.
2
Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, 00168 Rome, Italy.
3
Medical Oncology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
4
Laboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, "Sapienza" University, 00162 Rome, Italy.
5
Ophtalmology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, 00168 Rome, Italy.
6
Pathology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, 00168 Rome, Italy.

Abstract

No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.

KEYWORDS:

IDO; PD-L1; checkpoint inhibitors; immunotherapy; ipilimumab; nivolumab; pembrolizumab; uveal melanoma

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center